These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26206012)

  • 41. Budesonide MMX and mesalamine to induce remission in patients with ulcerative colitis.
    Criscuoli V; Sinagra E; Cottone M
    Gastroenterology; 2013 Mar; 144(3):e23. PubMed ID: 23352592
    [No Abstract]   [Full Text] [Related]  

  • 42. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
    Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
    Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.
    Gross V; Bar-Meir S; Lavy A; Mickisch O; Tulassay Z; Pronai L; Kupcinskas L; Kiudelis G; Pokrotnieks J; Kovács A; Faszczyk M; Razbadauskas A; Margus B; Stolte M; Müller R; Greinwald R;
    Aliment Pharmacol Ther; 2006 Jan; 23(2):303-12. PubMed ID: 16393311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A rational approach to 5-aminosalicylic acid therapy in ulcerative colitis.
    Miner PB; Peppercorn MA; Targan SR
    Hosp Pract (Off Ed); 1993 Dec; 28 Suppl 3():1-24. PubMed ID: 8270648
    [No Abstract]   [Full Text] [Related]  

  • 45. [Intestinal mucosa as the focal point. In distal ulcerative colitis relief with topical therapy].
    MMW Fortschr Med; 2004 Jun; 146(23):62-3. PubMed ID: 15373138
    [No Abstract]   [Full Text] [Related]  

  • 46. [Topical therapy of ulcerative colitis].
    Rogler G; Beglinger C; Mottet C; Seibold F; Gross V
    Praxis (Bern 1994); 2011 Nov; 100(23):1413-24. PubMed ID: 22086380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia.
    Piccin A; Cortelazzo S; Rovigatti U; Bourke B; Smith OP
    Am J Hematol; 2010 Aug; 85(8):634. PubMed ID: 20568248
    [No Abstract]   [Full Text] [Related]  

  • 49. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease.
    Siegel CA
    Gastroenterology; 2009 Dec; 137(6):1880-2. PubMed ID: 19879213
    [No Abstract]   [Full Text] [Related]  

  • 50. [Patients need no longer plan meals. Colitis therapy is simplified].
    MMW Fortschr Med; 2002 Mar; 144(13):52. PubMed ID: 12001596
    [No Abstract]   [Full Text] [Related]  

  • 51. Preparation and evaluation of mesalamine collagen in situ rectal gel: a novel therapeutic approach for treating ulcerative colitis.
    Ramadass SK; Perumal S; Jabaris SL; Madhan B
    Eur J Pharm Sci; 2013 Jan; 48(1-2):104-10. PubMed ID: 23137838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-daily mesalamine (Lialda) for ulcerative colitis.
    Med Lett Drugs Ther; 2007 Mar; 49(1257):25-6. PubMed ID: 17375030
    [No Abstract]   [Full Text] [Related]  

  • 53. [S3 guideline by the German Society of Digestive and Metabolic Diseases and the Competence Network of Chronic Inflammatory Bowel diseases on diagnosis and therapy of ulcerative colitis. An update].
    Hoffmann JC; Zeitz M;
    Med Klin (Munich); 2005 Jan; 100(1):43-50. PubMed ID: 15654542
    [No Abstract]   [Full Text] [Related]  

  • 54. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. "Take your medicine": nonadherence issues in patients with ulcerative colitis.
    Turnbough L; Wilson L
    Gastroenterol Nurs; 2007; 30(3):212-7; quiz 218-9. PubMed ID: 17568260
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute pancreatitis after long-term 5-aminosalicylic acid therapy.
    Fernández J; Sala M; Panés J; Feu F; Navarro S; Terés J
    Am J Gastroenterol; 1997 Dec; 92(12):2302-3. PubMed ID: 9399776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis.
    Connolly MP; Poole CD; Currie CJ; Marteau P; Nielsen SK
    Digestion; 2009; 80(4):241-6. PubMed ID: 19828955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of Budesonide-MMX in active ulcerative colitis.
    Gionchetti P; Praticò C; Rizzello F; Calafiore A; Capozzi N; Campieri M; Calabrese C
    Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):215-22. PubMed ID: 24502535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug Points: Anaphylactic-like reaction associated with oral budesonide.
    Heeringa M; Zweers P; de Man RA; de Groot H
    BMJ; 2000 Oct; 321(7266):927. PubMed ID: 11030679
    [No Abstract]   [Full Text] [Related]  

  • 60. [Survey on Patient Satisfaction with the Usability and Formulation of Budesonide Rectal Foam Following a Change in Head and Applicator Shape and Properties].
    Ishihara T; Hirata I; Konaka M; Hamaguchi M; Funakoshi R
    Yakugaku Zasshi; 2024; 144(10):951-956. PubMed ID: 39358251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.